Clinical Trial Search

Primary: Change in Melasma Area and Severity Index (MASI) Score — -11.4 units on a scale — p=0.006

Primary: Change From Baseline in Melasma Severity Rating Scale Score to Week 12 — 2.1; 2.1; -0.3; -0.8 score on a scale — p=0.041

Primary: Visual Analog Scale (VAS) of Improvement Rated by a Blinded Dermatologist From at Week 10 — 4.37; 4.62 units on a scale

Primary: Melasma Area Severity Assessment (MASI) Score Change From Baseline to Follow Up — -5.6; 4.7 score on a scale

Primary: Number of Participants Showing Improvement of Melasma Based on Mexameter Readings — 18 participants

Primary: Proportion of Patients With Moderate to Severe Hypopigmentation and Hyperpigmentation Assessed After Treatment — 0; 0 participants

Primary: Global Wrinkling - Change From Baseline to Week 12, Averaged Expert Grader Scores — 0.18; 0.30 Units on a scale — p=<0.001

Primary: Change in Spots - Front of Face (Part 1) — 53.60; 58.47; 56.44 spots

Primary: Change in Dyspigmentation Spots — 48.3; 46; 42.2; 42.5 Dyspigmentation Spots

Primary: The Change in Number of Facial Inflammatory Acne-related Lesions. — 46; 23.7 Lesions

Primary: Frequency of BRAF Mutations Among Nevi — 6; 19 BRAF mutations

Primary: Lab* Values of Lesional Area Using Dermoscopy and ImageJ — 68.850; 72.103; 73.147; 72.633 unitless

Primary: Change in Wrinkles From Baseline to 12 Weeks Post-study Treatment Assessed by Blinded Photographic Evaluation Using 9-Point Fitzpatrick Wrinkle Scale

Primary: Pigmented Lesion Improvement by Blinded Evaluation — 41 Observations

Primary: Solar Lentigines Count — 25.7; 26.0; 8.0; 11.0 Number of solar lentigines

Primary: Proportion of Success, Defined as Improvement of at Least 2 Grades From Baseline According to the IGA Scale Based on Facial Assessment — 16; 14.58; 11.54 Percentage of…

Primary: Percent Clearance of All Lesions — 88; 96; 92.5; 0 percentage of lesion clearance

Primary: Median VAS Improvement Score as Assessed by Blinded Physician Reviewers — 1.5 units on a scale — p=<0.0001

Primary: Severity of PLE Related Pruritus Recorded Using an 11-point Likert Scale — 0.25; 0.47 score on a scale

Primary: The Primary Endpoint for This Study Will be a Change From Baseline in the Number of Pigmented Lesions on Skin Previously Covered by Psoriatic Plaques. — 0 participants

Primary: Change in Hyperpigmentation of the Face — .8; .3; .45; .56 units on a scale — p=0.05

Primary: UV-induced Oxidative Stress in Irradiated and Unirradiated Nevi — 94.6; 96.2; 33.6; 33.1 percentage of 8-OG expression in nevi — p=.65

Primary: Percentage of Participants With Complete Response at Week 12 — 25.3; 23.0 percentage of participants

Primary: Photographic Evaluation Using the Blinded Global Aesthetic Improvement Scale — 0; 1; 3; 3 Participants

Primary: Within-subject Comparison of Dermal Reaction by the Overall Numeric Rating of Erythema and Edema at 5 Defined Test Sites, After Application of MC2-01 Cream, MC2-01…

Primary: Efficacy Outcome — 2.31; 1.15 units on a scale

Primary: Sensitivity and Specificity — 98.2; 9.5 Ratio * 100 — p=0.05

Primary: Histological Lesion Clearance — 38.5; 69.2 percentage of complete histological clea

Primary: Number of Participants With Evaluator (Dermatologist) Global Assessment (EGA) Score for Well Tolerance of Product 14 Days Post-Procedure — 36; 38 Participants — p=0.3334